Parkside Financial Bank & Trust’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $114K | Sell |
1,422
-101
| -7% | -$8.33K | 0.01% | 640 |
|
|
2025
Q4 | $130K | Buy |
1,523
+59
| +4% | +$4.84K | 0.01% | 601 |
|
|
2025
Q3 | $114K | Buy |
1,464
+9
| +0.6% | +$703 | 0.01% | 620 |
|
|
2025
Q2 | $114K | Buy |
1,455
+130
| +10% | +$9.7K | 0.01% | 605 |
|
|
2025
Q1 | $96K | Buy |
1,325
+28
| +2% | +$2K | 0.01% | 597 |
|
|
2024
Q4 | $96K | Buy |
1,297
+205
| +19% | +$14.3K | 0.01% | 584 |
|
|
2024
Q3 | $72.1K | Sell |
1,092
-109
| -9% | -$7.92K | 0.01% | 648 |
|
|
2024
Q2 | $111K | Buy |
1,201
+107
| +10% | +$9.47K | 0.02% | 489 |
|
|
2024
Q1 | $105K | Sell |
1,094
-31
| -3% | -$2.6K | 0.02% | 513 |
|
|
2023
Q4 | $85.8K | Buy |
1,125
+164
| +17% | +$11.4K | 0.02% | 528 |
|
|
2023
Q3 | $66.6K | Sell |
961
-209
| -18% | -$16.8K | 0.02% | 532 |
|
|
2023
Q2 | $110K | Buy |
1,170
+27
| +2% | +$2.35K | 0.03% | 387 |
|
|
2023
Q1 | $94.6K | Buy |
1,143
+99
| +9% | +$7.78K | 0.03% | 407 |
|
|
2022
Q4 | $77.9K | Buy |
1,044
+50
| +5% | +$3.85K | 0.02% | 443 |
|
|
2022
Q3 | $82K | Buy |
994
+44
| +5% | +$4.23K | 0.03% | 389 |
|
|
2022
Q2 | $90K | Sell |
950
-2
| -0.2% | -$207 | 0.03% | 369 |
|
|
2022
Q1 | $112K | Buy |
952
+86
| +10% | +$9.65K | 0.03% | 337 |
|
|
2021
Q4 | $112K | Buy |
866
+166
| +24% | +$19.4K | 0.03% | 342 |
|
|
2021
Q3 | $79K | Buy |
700
+84
| +14% | +$9.59K | 0.02% | 372 |
|
|
2021
Q2 | $64K | Buy |
616
+19
| +3% | +$1.79K | 0.02% | 438 |
|
|
2021
Q1 | $50K | Buy |
597
+18
| +3% | +$1.52K | 0.02% | 484 |
|
|
2020
Q4 | $53K | Buy |
579
+16
| +3% | +$1.33K | 0.02% | 447 |
|
|
2020
Q3 | $45K | Sell |
563
-1
| -0.2% | -$78 | 0.02% | 434 |
|
|
2020
Q2 | $39K | Buy |
564
+39
| +7% | +$2.77K | 0.01% | 473 |
|
|
2020
Q1 | $33K | Sell |
525
-198
| -27% | -$14.3K | 0.01% | 448 |
|
|
2019
Q4 | $56K | Sell |
723
-27
| -4% | -$2.11K | 0.02% | 411 |
|
|
2019
Q3 | $55K | Hold |
750
| – | – | 0.02% | 386 |
|
|
2019
Q2 | $46K | Buy |
750
+9
| +1% | +$544 | 0.01% | 416 |
|
|
2019
Q1 | $47K | Buy |
741
+282
| +61% | +$16.1K | 0.02% | 392 |
|
|
2018
Q4 | $23K | Buy |
459
+156
| +51% | +$7.89K | 0.01% | 530 |
|
|
2018
Q3 | $17K | Sell |
303
-6
| -2% | -$293 | 0.01% | 644 |
|
|
2018
Q2 | $15K | Buy |
309
+27
| +10% | +$1.26K | 0.01% | 657 |
|
|
2018
Q1 | $13K | Buy |
282
+72
| +34% | +$3.13K | ﹤0.01% | 666 |
|
|
2017
Q4 | $8K | Sell |
210
-381
| -64% | -$14K | ﹤0.01% | 775 |
|
|
2017
Q3 | $22K | Sell |
591
-90
| -13% | -$3.43K | 0.01% | 515 |
|
|
2017
Q2 | $27K | Buy |
681
+243
| +55% | +$8.87K | 0.01% | 458 |
|
|
2017
Q1 | $14K | Sell |
438
-600
| -58% | -$18.8K | 0.01% | 614 |
|
|
2016
Q4 | $32K | Sell |
1,038
-738
| -42% | -$23.9K | 0.01% | 423 |
|
|
2016
Q3 | $71K | Buy |
1,776
+570
| +47% | +$21.5K | 0.03% | 298 |
|
|
2016
Q2 | $40K | Sell |
1,206
-87
| -7% | -$2.98K | 0.02% | 387 |
|
|
2016
Q1 | $38K | Sell |
1,293
-87
| -6% | -$2.4K | 0.02% | 388 |
|
|
2015
Q4 | $36K | Buy |
1,380
+114
| +9% | +$2.96K | 0.02% | 392 |
|
|
2015
Q3 | $30K | Buy |
+1,266
| New | +$30.6K | 0.02% | 398 |
|
Other funds holding EW
VCM
VPM
Parkside Financial Bank & Trust's EW Position: Q1 2026 in Review
Parkside Financial Bank & Trust reduced its Edwards Lifesciences (EW) stake by 6.6% in Q1 2026, selling an estimated $8.33K and leaving 1,422 shares worth $114K. The position accounts for 0.01% of the portfolio, ranked #640.
Parkside Financial Bank & Trust first reported a position in EW in Q3 2015 and has held it in 43 quarters since. The position peaked at $130K in Q4 2025. 1,287 funds tracked by Wall St. Rank hold EW as of Q1 2026.
- Parkside Financial Bank & Trust held 1,422 shares of Edwards Lifesciences worth $114K as of Q1 2026.
- Parkside Financial Bank & Trust sold 101 Edwards Lifesciences shares in Q1 2026, an estimated $8.33K.
- Edwards Lifesciences made up 0.01% of Parkside Financial Bank & Trust's portfolio in Q1 2026, its #640 holding.
- Parkside Financial Bank & Trust first reported a position in Edwards Lifesciences in Q3 2015 and has held it in 43 quarters since.
- Parkside Financial Bank & Trust's Edwards Lifesciences position peaked at $130K in Q4 2025.
- 1,287 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.
Based on Parkside Financial Bank & Trust's 13F filing for Q1 2026, filed 13 May 2026.